Morgan Stanley Maintains Overweight on Treace Medical Concepts, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Drew Ranieri has maintained an Overweight rating on Treace Medical Concepts (NASDAQ:TMCI) but reduced the price target from $30 to $14.
November 13, 2023 | 1:41 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained its Overweight rating on Treace Medical Concepts but has lowered the price target from $30 to $14.
The reduction in price target by Morgan Stanley, despite maintaining an Overweight rating, could lead to a negative short-term sentiment among investors, potentially causing a decrease in TMCI's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100